The role of catestatin in left ventricular myocardial remodelling in patients with combined cardiometabolic pathology

  • Received 02.10.2025

  • Revised 28.01.2026

  • Accepted 24.02.2026

  • Published 25.03.2026


  • 174 Views

  • Retrieved from Vol. 8, No. 1, 2026

  • Pages 28-35

The study is necessitated by the need to investigate the effect of catestatin on the structural and functional myocardial state in patients with chronic heart failure under conditions of cardiometabolic polymorbidity (type 2 diabetes mellitus and obesity). The aim was to evaluate the role of catestatin in the formation of structural and functional changes in the myocardium in patients with chronic heart failure in coronary artery disease with concomitant type 2 diabetes mellitus and obesity. The study involved 225 patients who were divided into four groups depending on the presence of metabolic disorders. A transthoracic echocardiographic examination was performed to assess the morphofunctional state of the myocardium. The level of catestatin in blood serum was determined by immunoenzymatic method. Spearman’s correlation coefficient was used to assess the degree of correlation. The results showed that the most unfavourable indicators of left ventricular remodelling, including the maximum increase in end-systolic volume (101.57 mL) and end-diastolic volume (192.16 mL), as well as the lowest ejection fraction (42.67%), were recorded in patients with a combination of chronic heart failure, coronary artery disease, type 2 diabetes mellitus and obesity. This group had the lowest level of catestatin (1.53 ng/mL), which was 78.0% lower than in patients without metabolic disorders. Correlation analysis confirmed a strong direct relationship between catestatin levels and left ventricular ejection fraction (r=0.68), as well as strong inverse correlations with end-diastolic volume (r=−0.69) and end-systolic volume (r=−0.67). A decrease in catestatin concentration is closely associated with an increase in left ventricular volume, its pathological remodelling, and a decrease in pumping function. The presence of polymorbid pathology leads to the most pronounced dilated type of left ventricular remodelling, and low catestatin levels are not only a marker but also a probable participant in the pathogenesis of adverse structural and functional changes in the myocardium

chronic heart failure; coronary artery disease; type 2 diabetes mellitus; obesity; morpho-functional state of the myocardium

https://doi.org/10.63341/bmbr/1.2026.28
  1. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: An updated review. Card Fail Rev. 2023;9:e11. DOI: 10.15420/cfr.2023.05
  2. Sotomayor-Julio AD, Seni-Molina S, Gutiérrez-Posso JM, Muñoz-Ordoñez JA, Azcárate-Rodríguez V, León-Giraldo HO, et al. Characterisation of 2,500 patients with heart failure and analysis of their optimal medical therapy: Insights from the AMERICCAASS registry. Glob Heart. 2025;20(1):27. DOI: 10.5334/gh.1418
  3. Mankovskyi HB, Marushko YeYu, Dzhun YaYu, Stychynskyi OS. Mechanisms of ischemic heart disease development in type 2 diabetes patients based on renal function. Ukr J Cardiovasc Surg. 2024;32(4):61–6. DOI: 10.30702/ujcvs/24.32(04)/MM069-6166
  4. Mazurkiewicz M, Bodnar P, Blachut D, Chwalba T, Wagner W, Barczyk E, et al. Adipokines and adipose tissue: The role and use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with diabetes or heart failure. Biomedicines. 2025;13(5):1098. DOI: 10.3390/biomedicines13051098
  5. Shelest BO, Kovalova YuO, Shelest OM, Rodionova YuV, Hilova YaV. Combined influence of diabetes mellitus and obesity on left ventricle remodelling in hypertensive patients. Zaporozhye Med J. 2021;23(1):46–51. DOI: 10.14739/2310-1210.2021.1.224880
  6. von Jeinsen B, Vasan RS, McManus DD, Mitchell GF, Cheng S, Xanthakis V. Joint influences of obesity, diabetes, and hypertension on indices of ventricular remodelling: Findings from the community-based Framingham Heart Study. PLoS One. 2020;15(12):e0243199. DOI: 10.1371/journal.pone.0243199
  7. Appunni S, Rubens M, Ramamoorthy V, Saxena A, McGranaghan P, Khosla A, et al. Molecular remodelling in comorbidities associated with heart failure: A current update. Mol Biol Rep. 2024;51(1):1092. DOI: 10.1007/s11033-024-10024-7
  8. Zalewska E, Kmieć P, Sworczak K. Role of catestatin in the cardiovascular system and metabolic disorders. Front Cardiovasc Med. 2022;9:909480. DOI: 10.3389/fcvm.2022.909480
  9. Kulpa J, Paduch J, Szczepanik M, Gorący-Rosik A, Rosik J, Tchórz M, et al. Catestatin in cardiovascular diseases. Int J Mol Sci. 2025;26(6):2417. DOI: 10.3390/ijms26062417
  10. Qiu Z, Fan Y, Wang Z, Huang F, Li Z, Sun Z, et al. Catestatin protects against diastolic dysfunction by attenuating mitochondrial reactive oxygen species generation. J Am Heart Assoc. 2023;12(9):e029470. DOI: 10.1161/JAHA.123.029470
  11. Izci S, Acar E, Inanir M. Plasma catestatin level predicts sPESI score and mortality in acute pulmonary embolism. Arch Med Sci Atheroscler Dis. 2020;5(1):49–56. DOI: 10.5114/amsad.2020.95562
  12. World Health Organization. Body mass index (BMI) [Internet]. [cited 2025 August 18]. Available from: https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index
  13. Shrestha B, Dunn L. The Declaration of Helsinki on Medical Research involving Human Subjects: A Review of Seventh Revision. J Nepal Health Res Counc. 2020;17(4):548–52. DOI: 10.33314/jnhrc.v17i4.1042
  14. Have HAMJ, Jean MS, editors. The UNESCO Universal Declaration on Bioethics and Human Rights: Background, principles and application. Paris: UNESCO Publishing; 2009. 370 P.
  15. Mahata SK, Mahata M, Fung MM, O’Connor DT. Reprint of: Catestatin: A multifunctional peptide from chromogranin A. Regul Pept. 2010;165(1):52–62. DOI: 10.1016/j.regpep.2010.09.007
  16. Zalewska E, Kmieć P, Sobolewski J, Koprowski A, Sworczak K. Low catestatin as a risk factor for cardiovascular disease – assessment in patients with adrenal incidentalomas. Front Endocrinol (Lausanne). 2023;14:1198911. DOI: 10.3389/fendo.2023.1198911
  17. Rathee JS, Iyer DR, Kiranmayi M, Reddy S, Sureshbabu VV, Mahapatra NR. The physiological anti-hypertensive peptide catestatin and its common human variant Gly364Ser: Differential cardiovascular effects in a rat model of hypertension. Biosci Rep. 2024;44(12):BSR20241433. DOI: 10.1042/BSR20241433
  18. Yan Q, Liu S, Sun Y, Chen C, Yang S, Lin M, et al. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. J Transl Med. 2023;21(1):519. DOI: 10.1186/s12967-023-04361-7
  19. Zhu D, Xie H, Wang X, Liang Y, Yu H, Gao W. Catestatin – a novel predictor of left ventricular remodelling after acute myocardial infarction. Sci Rep. 2017;7:44168. DOI: 10.1038/srep44168
  20. Wołowiec Ł, Rogowicz D, Banach J, Gilewski W, Sinkiewicz W, Grześk G. Catestatin as a new prognostic marker in stable patients with heart failure with reduced ejection fraction in two-year follow-up. Dis Markers. 2020;2020(1):8847211. DOI: 10.1155/2020/8847211
  21. Chu SY, Peng F, Wang J, Liu L, Zhao J, Han XN, et al. Catestatin as a predictor for cardiac death in heart failure with mildly reduced and preserved ejection fraction. ESC Heart Fail. 2025;12(1):517–24. DOI: 10.1002/ehf2.15107
  22. Gallo MP, Femminò S, Antoniotti S, Querio G, Alloatti G, et al. Catestatin induces glucose uptake and GLUT4 trafficking in adult rat cardiomyocytes. Biomed Res Int. 2018;2018:2086109. DOI: 10.1155/2018/2086109
  23. Dunaieva I, Bilovol O. Catestatin in diagnosing cardiovascular and metabolic disorders in patients with comorbid hypertension. Int Endocrinol J. 2023;19(4):319–24. DOI: 10.22141/2224-0721.19.4.2023.1293
  24. Borovac JA, Glavas D, Susilovic Grabovac Z, Supe Domic D, D’Amario D, Bozic J. Catestatin in acutely decompensated heart failure patients: Insights from the CATSTAT-HF study. J Clin Med. 2019;8(8):1132. DOI: 10.3390/jcm8081132